View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 25, 2022

FDA approves Medtronic neurostimulators to treat chronic pain from DPN

A neurological disorder, diabetic peripheral neuropathy (DPN) impacts around 30% of people with diabetes.

The US Food and Drug Administration (FDA) has approved Medtronic’s Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator to treat chronic pain related to diabetic peripheral neuropathy (DPN).

Free Report
img

Find the right pricing strategy for your medical device

How do your competitors set prices in different markets? Will reducing your prices win market share from your main competitors? Do you need to position products differently for different markets? To find out, use our Global Brand Pricing tool to achieve optimal pricing for your devices. Detect price changes, understand competitor market positioning, and plan new product launches, by accessing this tool today. It features:
  • A proprietary algorithm that leverages numerous pricing sources, with an emphasis on real-world data
  • Estimates of the likely spread of selling prices per brand and manufacturer, as well as 3-year forecasts for prices
  • Medical device pricing data that can be tracked by market, company, and brand
  • Additional categories that can be built on a custom basis
Use our tool to access competitor pricing strategies across multiple geographies, and various dynamic case studies from the likes of Germany and China, to benchmark yourself against your competitors and future proof your pricing strategies.
by GlobalData
Enter your details here to receive your free Report.

DPN is a neurological disorder that impacts around 30% of people with diabetes.

The approval offers DPN patients access to Medtronic’s spinal cord stimulation (SCS) portfolio of both rechargeable and recharge-free platforms.

These platforms include multiple programming options for customising patient treatment, unrestricted MRI access and the Medtronic TYRX neuro absorbable antibacterial envelope.

The company stated that the TYRX antibacterial envelope has been shown to stabilise the placement of the device while reducing more than 60% of infections.

It also noted that clinicians may advise patients to use CareGuidePro, a virtual guide for patients using SCS offerings.

Medtronic Neuroscience Portfolio neuromodulation business pain therapies vice-president and general manager Charlie Covert said: “DPN is a significant challenge for patients with diabetes, leading to disability and a diminished quality of life.

“This new indication enables us to apply Medtronic’s more than 40 years of proven SCS experience, as well as the company’s deep diabetes expertise, to deliver better care to even greater numbers of diabetes patients.”

According to the company’s estimates, up to 800,000 patients in the US suffer from moderate to severe DPN symptoms that do not get resolved through conventional medical management approaches, such as drugs. 

It considers such patients as potential candidates for SCS, which in turn represents an annual market opportunity of around $1.8bn.

The firm estimates that the market revenue for SCS treatment of chronic pain related to DPN is around $70m in the US. This figure is expected to increase to $300m by 2026.

Recently, Medtronic agreed to acquire medical technology company Affera in a deal valued at $925m.

Related Companies

Free Report
img

Find the right pricing strategy for your medical device

How do your competitors set prices in different markets? Will reducing your prices win market share from your main competitors? Do you need to position products differently for different markets? To find out, use our Global Brand Pricing tool to achieve optimal pricing for your devices. Detect price changes, understand competitor market positioning, and plan new product launches, by accessing this tool today. It features:
  • A proprietary algorithm that leverages numerous pricing sources, with an emphasis on real-world data
  • Estimates of the likely spread of selling prices per brand and manufacturer, as well as 3-year forecasts for prices
  • Medical device pricing data that can be tracked by market, company, and brand
  • Additional categories that can be built on a custom basis
Use our tool to access competitor pricing strategies across multiple geographies, and various dynamic case studies from the likes of Germany and China, to benchmark yourself against your competitors and future proof your pricing strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network